The effects of interferon-β treatment on synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis

Arthritis and Rheumatism

Volumn 43, Issue 2, 2000, Pages 270-274

  Smeets, Tom J M ^a   Dayer, Jean M ^b   Kraan, Maarten C ^a   Versendaal, Johannes ^c   Chicheportiche, Rachel ^b   Breedveld, Ferdinand C ^c   Tak, Paul P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD3 ANTIGEN; COLLAGENASE; DECAY ACCELERATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; METALLOPROTEINASE; PROSTAGLANDIN E2; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANTIBODY SPECIFICITY; ARTHROSCOPY; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; SYNOVIOCYTE; SYNOVITIS;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ARTHRITIS, RHEUMATOID; DINOPROSTONE; FEMALE; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-BETA; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; METALLOENDOPEPTIDASES; MIDDLE AGED; SYNOVIAL MEMBRANE; SYNOVITIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 0034042091     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200002)43:2<270::AID-ANR5>3.0.CO;2-H     Document Type: Article

References (15)

1. Tak PP, 't Hart BA, Kraan MC, Jonker M, Smeets TJM, Breedveld FC. The effects of interferon-beta treatment on arthritis. Rheumatology 1999;38:362-9.
2. Arnason BGW, Dayal A, Qu ZX, Jensen MA, Gene K, Reder AT. Mechanisms of action of interferon-beta in multiple sclerosis. Springer Semin Immunopathol 1996;18:125-48.
3. Van den Berg WB. Joint inflammation and cartilage destruction may occur uncoupled. Springer Semin Immunopathol 1998;20: 149-64.
4. Wee Yong V, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis; mechanisms of action. Neurology 1998;51:682-9.
5. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. Amelioration of collagen-induced arthritis and suppression of interferon-γ, interleukin-12, and tumor necrosis factor α production by interferon-β gene therapy. Arthritis Rheum 1999;42:90-9.
6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
7. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
8. Tak PP, van der Lubbe PA, Cauli A, Daha MR, Smeets TJM, Kluin PM, et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995;38:1457-65.
9. Youssef PP, Smeets TJM, Bresnihan B, Cunnane G, FitzGerald O, Breedveld F, et al. Microscopic measurement of cellular infiltration in the rheumatoid arthritis synovial membrane: a comparison of semiquantitative and quantitative analysis. Br J Rheumatol 1998;37:1003-7.
10. 2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8.
11. Calabresi PA, Tranquill LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol 1997;41:669-74.
12. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993;46:145-53.
13. Rep MHG, Hintzen RQ, Polman CH, van Lier RAW. Recombinant interferon beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol 1996;67:111-8.
14. Ferrarini AM, Sievieri S, Buttarello M, Facchinetti A, Perini P, Gallo P. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients. Mult Scler 1998;4:174-7.
15. Fierlbeck G, Schreiner T. Incidence and clinical significance of therapy-induced neutralizing antibodies against interferon-beta. J Interferon Res 1994;14:417-25.